Table 2. . RTOG 9402: molecular subtyping and response to RT versus RT + PCV.
| Molecular signature | Frequency (%) | Median overall survival (years) | |
|---|---|---|---|
| Radiotherapy | Radiotherapy + PCV | ||
| IDH1 mutation | 74 | 5.7 | 9.4 |
| IDH wild-type | 26 | 1.3 | 1.8 |
| 1p19q codeletion + IDH1 mutation (90% codeleted tumors w/IDH1 mutation; 78% AO) | 42 | 6.8 | 14.7 |
| Nondeleted + IDH1 mutation (64% AOA; 72% ATRX mutated) | 32 | 3.3 | 5.5 |
| + ATRX mutation | 2.7 | 11.0 | |
| + ATRX wild-type | 3.5 | 4.4 | |
| Nondeleted + IDH1 wild-type | 21 | 1.0 | 1.3 |
| 1p19q codeletion + IDH1 wild-type | 5 | ||
Anaplastic oligodendroglial tumors = AO and AOA.
AO: Anaplastic oligodendroglioma; AOA: Anaplastic oligoastrocytoma; PCV: Procarbazine, lomustine (CCNU), vincristine.